THIRD QUARTER 2025 UPDATES, INCLUDING NEW PRODUCT ADDITION AND INTERNATIONAL EXPANSION
We’re thrilled to share several exciting developments from the third quarter of 2025, including the arrival of a new addition to our commercial product portfolio – Talicia®, a leading triple therapy for the treatment of Helicobacter pylori infections: Talicia features include three key advantages – high eradication rates at >90%, simplicity of an all in […]
SECOND QUARTER 2025 UPDATES INCLUDE NEW CLINICAL DATA & FINANCIAL MOMENTUM
We enjoyed a strong first half of the year! During the second quarter, our momentum continued, as we advanced our mission of working together to deliver favorable commercial and clinical development results. During the quarter we remained dedicated to advancing our mission of working together to provide unique products that improve the quality of patient […]
FIRST QUARTER 2025 UPDATES, INCLUDING BREAKTHROUGH PHASE 2 DMD STUDY RESULTS
Our approved brands remain a key driver of performance, while expanded international partnerships and steady advancement in our clinical development programs further strengthen our position. We are also evaluating select acquisition opportunities that align with our strategic objectives. As we look ahead, we remain committed to executing our growth strategy and delivering long-term value. We […]
EARLY 2025 MILESTONES
Cumberland’s business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We’ve also built an internal development capability, which enables us to develop and register new medicines, establishing a long-term pipeline for our business. We recently reported […]
November 2024 Updates, Highlighting Key Clinical and Business Developments
We are pleased to report several significant milestones that reinforce our mission of working together to provide unique products that improve the quality of patient care. Our latest updates include important research findings, growing Medicaid coverage and expanded product access. In October, we announced new real-world outcomes research comparing Caldolor® to its key competitor – […]
Second Quarter 2024 Updates, Including Double-Digit Revenue Growth
We were pleased to report that Cumberland delivered a strong financial performance for the second quarter. Our line of FDA-approved brands delivered just under $10 million in net revenues, which represented 16% in sequential growth from the first quarter of the year. During the quarter we remained dedicated to advancing our mission of working together […]
First Quarter 2024 Updates, Including a Special Report for Our Caldolor® Product
Overall, the first quarter proved to be a productive start to the year. Our Cumberland team remains dedicated to our mission of working together to provide unique products that improve the quality of patient care. During the quarter, we shared a number of exciting company updates, including several growth opportunities for our portfolio of brands. […]
2023 Highlights, Including Expanded FDA Approval And New Study Publications
In many ways 2023 was a building year for Cumberland, as we continued to integrate our newest products, while also delivering several significant achievements. We took a fresh look at our mission statement during the year and refined it to better capture the spirit of what we do each day at Cumberland Pharmaceuticals. It now […]
Third Quarter 2023 Updates, Including Our New Mission Statement
During the third quarter, we refined our mission statement to better capture the spirit of what we endeavor to do each day here at Cumberland Pharmaceuticals. It now reads as follows: working together to provide unique products that improve the quality of patient care We took several factors into account in designing this statement. First, […]
Second Quarter 2023 Updates, Including Expanded FDA Approval for Caldolor® and Publication of Newborn Clinical Study Results
In the second quarter of 2023, we advanced our business, as the operating environment continued to slowly improve from the post-pandemic challenges. Our team has been working diligently to maximize the potential of our commercial brands, progress our pipeline and pursue select acquisitions. We’re pleased to share several notable developments from an overall successful quarter: […]